ABSTRACT
Neuroleptics are considered to be the cornerstone in the treatment of schizophrenia. However their efficacy in controlling the positive symptoms of schizophrenia is offset by their relative lack of effect on negative symptoms such as blunted affect, emotional withdrawal, low motivation and drive, poor rapport and social withdrawal, furtherthe potent dopamine an-' tagonism exhibited by these agent is associated with a high occurrence of extrapyramidal symptoms. There has been a long-felt need for a drug effective against negative as well as positive symptoms with a lower propensity to cause extrapyramidal symptoms. A serotonin receptor antagonist added to a dopamine receptor antagonist, can improve psychotic symptoms (Reyntjens et al., 1986) and also alleviate neuroleptic induced parkinsonian side effects (Bersani et al., 1986; Hilderbrand and Delecluse, 1987; Bersani et al., 1990) . It has also been suggested that serotonin antagonism may improve the negative symptoms of schizophrenia (Bleich et al., 1988) . Risperidone, a benzisoxazole derivative is noval antipsychotic agent and chemically unrelated to conventional antipsychotics. It has blocking effects both on 5HT 2 and dopamine D 2 receptors (Leysen et al., 1988; Janssen et al., 1988) . Animal experiments have indicated its low potency in inducing extrapyramidal symptoms (EPS) . Early clinical trials suggested that risperidone is effective on both positive and negative symptoms of schizophrenia and causes a lower incidence of EPS (Roose et al., 1988; Gelders et al., 1990) . Subsequent double blind studies comparing it with haloperidol and perphanazine have confirmed these results Claus et al., 1992; Hoyberg et al., 1993) . Ceskova and Svestka (1993) , Borison et al. (1992) , Davis & Janicak (1994) , Marder (1996) have further proved the clinical efficacy of risperidone. Side effect profile of risperidone show that it produces less EPS in lower dosage but at higher dosage the rate of EPS is similar to haloperidol. However in the USCanada study the patients receiving risperidone 6 mg/day required same amount of antiparkinsonian medication as those on haloperidol.
Risperidone has been extensively tried in the west yet the drugs efficacy and tolerability in Indian patients has not been established. The present study was therefore undertaken with the following aims. 1. To assess the efficacy of risperidone in Indian patients suffering from schizophrenia. 2. To study the side effect profile of risperidone.
MATERIAL & METHOD
Inclusion criteria: Age between 16 and 65 years, either sex; diagnosis of schizophrenia according to DSM-IV criteria; informed consent from patients, or their relatives or legal guardians Exclusion criteria : Patients with clinically significant cardiac or heamatological disorders or with abnormal renal or hepatic laboratory tests ; pregnant or lactating women; patients with mental disorders other than chronic schizophrenia or acute exacerbation of chronic schizophrenia; patients who had received depot neuroleptics less than 4 weeks before entry into the study; patients with a history of alcohol or drug abuse; history of hypersensitivity to benzisoxazoles; patients with Parkinson's disease, narrow angle glaucoma or prostatic hypertrophy; patients who had a reduction of * 20% in total PANSS score after 1 week of placebo therapy.
Medication : The starting dose was 1 mg b.i.d. on day 1, stepped upto 2 mg b.i.d. on day 2 and 3 mg bid. thereafter for 3 weeks. At the end of 3 weeks, the dose was stepped up to 4 mg b.i.d. in patients who showed a reduction of <20% in total PANSS score; others continued to receive 3 mg bid. Completion of 6 weeks of active therapy with risperidone marked the end of the study for each patient.
Assessment : Assessment were made at weekly intervals on PANSS. Clinical improvement was defined as reduction of > 20% in total PANSS spore. The overall severity of illness was also assessed on the Clinical Global Impression (CGI) scale.
The Scandinavia Society of Pharmacology Committee on Clinical Investigations Scale (UKU Scale) was used to assess side effects.
As it was a multicentric study all investigators met for one day to establish uniformity across centres.
RESULTS
One hundred and seventy-seven patients were enrolled in this study at 6 centres in India. Eight patients did not receive active medication and four others who had received active medication did not report for post-therapy evaluations. Seventeen patients were lost to follow-up. One hundred forty six patients completed the study per protocol.
The demographic and clinical profile of patients is shown in table 1. Clinical improvement (reduction of 20% or more in , PANSS total score) in the intent to treat and per protocol population is shown in table 2.
In the per protocol population, 75 patients received risperidone 3 mg b.i.d. for 6 weeks and in 71 patients the dose was stepped up from 3 mg b.i.d. to 4 mg b.i.d. due to inadequate The majority of adverse events were mild to moderate in intensity. However, a decrease intensity was noted in some of the adverse events which were of severe intensity at baseline : five patients with decreased duration of sleep, four patients with emotional indifference, three patients with tension/inner unrest, three patients with decreased sexual desire and one patient with decreased duration of sleep. In these patients intensity was reduced to mild or One case of the overdosage with trihexyphenidyl occurred during the study (twenty five tablets of trihexyphenidyl).This patient was delerious for 1 day. He was managed conservatively and risperidone was restarted after 2 days. This patients also had allergic rhinitis with nasal congestion, sinusitis and a single episode of bronchial asthma.
One patient requested to be withdrawn from study after 1 week of risperidone therapy. He developed tension/inner unrest, akathisia, reduced salivation of severe intensity, tremor, rigidity and polyuria/polydipsia of moderate intensity Trihexyphenidyl for parkinsonian symptoms was required in 72 (47.4%) patients, lorazepam for sedation in 51 (30.9%) patients and propranalol for control of tremor in 7 (4.2%) patients. Some patients needed more than one of the above medications.
DISCUSSION
The clinical efficacy and tolerability (40) 9 (5.5) 8 (4.8) 13 (7 9) 10(6.1) 11 (6.7) 1 (0.6) 4 (2.4) 3 (18) 15(9.1) 12(7.3) 11 (6.7) 2(1. of risperidone therapy observed in the present study is in line with other studies demonstrating that risperidone is an erfective and well tolerated antipsychotic (Kane et al., 1988; Leysen et al., 1988; Megens et al., 1988; Muller-Spahn, 1992) (Roose et al., 1988) . Patients refractory to other antipsychotics viz. haloperidol, chlorpromazine, trifluoperazine, fluphenazine & pimozide used alone or in combinations also posted significant responses. Adverse experiences were already present in 65.7% patients at baseline i.e. after a washout period of one week from previous antipsychotic medication; this increased to 72.7% of patients at the end of therapy. Extrapyramidal symptoms were largely mild to moderate in intensity and need for antiparkinsonian medication was considerably lower than reported for conventional antipsychotics. Concentration difficulties, depression, reduced duration of sleep, tension/inner unrest, emotional indifference, diminished sexual desire and headache improved with risperidone therapy in a number of patients. Increased salivation and postural dizziness seen in 12.1% and 6.7% patients respectively were largely mild to moderate and transient. A fall in systolic blood pressure of 10 mmHg with postural dizziness was seen in 1 patients only. Only one patient requested to be withdrawn because of severe adverse events. There were no serious adverse events. Thus risperidone was well tolerated. Increasing the dosage from 3 mg bid. to 4 mg b.i.d. resulted in a somewhat higher incidence of adverse events but resulted in a greater proportion of patients responding to risperidone ' therapy.
In conclusion, risperidone was effective in the treatment of Indian patients with schizophrenia. Both positive and negative symptoms were ameliorated. Clinical improvement was noted in 87 7% of patients by the end of 6 weeks of risperidone therapy. Risperidone was effective in 17 of the 25 patients refractory to treatment with haloperidol, chlorpromazine, trifluoperazine, fluphenazine or pimozide used alone or in combination.
The drug was well tolerated. Side effects were largely mild to moderate in intensity. Extrapyramidal symptoms and need for antiparkinsonian medication were considerably lower than reported for conventional antipsychotics.
Because of its high efficacy, relief of negative symptoms, efficacy in patients refractory to conventional antipsychotics, good tolerability and freedom from serious adverse events risperidone would be an important antipsychotic drug for the treatmeat of schizophrenia in Indian patients.
